Bayer AG (FRA:BAYN) received a €121.00 ($140.70) price objective from equities researchers at Berenberg Bank in a research report issued on Thursday, October 26th. The firm presently has a “neutral” rating on the healthcare company’s stock. Berenberg Bank’s price target would indicate a potential upside of 10.20% from the stock’s current price.
A number of other equities research analysts also recently weighed in on the company. J P Morgan Chase & Co restated a “buy” rating on shares of Bayer AG in a research report on Wednesday, September 13th. Goldman Sachs Group, Inc. (The) set a €125.00 ($145.35) price target on Bayer AG and gave the company a “buy” rating in a research report on Monday, July 24th. Deutsche Bank AG set a €124.00 ($144.19) price objective on Bayer AG and gave the company a “buy” rating in a research note on Monday, July 10th. Citigroup Inc. reaffirmed a “buy” rating on shares of Bayer AG in a research note on Wednesday, July 5th. Finally, Commerzbank Ag set a €124.00 ($144.19) target price on Bayer AG and gave the stock a “buy” rating in a research note on Monday, August 28th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and thirteen have assigned a buy rating to the company. Bayer AG currently has an average rating of “Buy” and an average price target of €122.48 ($142.41).
Shares of Bayer AG (BAYN) traded down €0.90 ($1.05) during mid-day trading on Thursday, hitting €109.80 ($127.67). The company had a trading volume of 2,252,260 shares. Bayer AG has a one year low of €85.72 ($99.67) and a one year high of €123.82 ($143.98).
ILLEGAL ACTIVITY NOTICE: “Berenberg Bank Reiterates €121.00 Price Target for Bayer AG (FRA:BAYN)” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2017/11/12/bayer-ag-bayn-given-a-121-00-price-target-by-berenberg-bank-analysts.html.
About Bayer AG
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.